Biomea Fusion presents preclinical data for BMF-500 at ASH; IND on track for H1 2023

Biomea Fusion, Inc.

BMF-500 demonstrated picomolar affinity to FLT3 mutations, including ITD and TKD.
Complete tumor regression in FLT3-ITD xenograft models; effect maintained without continuous exposure.
Three-hour pulse of BMF-500 outperformed continuous gilteritinib exposure in cell killing.
IND submission for BMF-500 planned for first half of 2023.
BMF-500 showed high selectivity with minimal off-target cytotoxicity across 20 cancer cell lines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.